GNG12-AS1: A Potential Drug Target and Biomarker (G100289178)

Target Name: GNG12-AS1

NCBI ID: G100289178

GNG12-AS1

Other Name(s): GNG12 antisense RNA 1 (non-protein coding) | GNG12, DIRAS3 and WLS antisense RNA 1

GNG12-AS1: A Potential Drug Target and Biomarker

Gene Nucleotide GNN Hypothetical Deletion

Gene Nucleotide GNN Hypothetical Deletion (GNG12-AS1) is a gene that has gained significant attention due to its involvement in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The GNG12-AS1 gene has been identified as a potential drug target and biomarker for several reasons. This article will discuss the GNG12-AS1 gene, its potential drug target status, and its potential as a biomarker for various diseases.

Potential Drug Target

The GNG12-AS1 gene is located on chromosome 12q34 and encodes for a protein known as GNG12-AS1. GNG12-AS1 plays a crucial role in the regulation of cell growth, apoptosis, and inflammation. It is known to be involved in the development and progression of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

One of the promising aspects of the GNG12-AS1 gene is its potential as a drug target. GNG12-AS1 has been shown to be involved in the regulation of cell cycle progression, apoptosis, and inflammation, making it an attractive target for small molecules. Several studies have shown that inhibitors of GNG12-AS1 can lead to the inhibition of cell proliferation and the inhibition of neurodegeneration in various models.

In addition, GNG12-AS1 has been shown to be involved in the regulation of cellular immigration, a critical process in the development of cancer and neurodegenerative diseases. Therefore, targeting GNG12-AS1 may be an effective way to treat these diseases.

Biomarker

GNG12-AS1 has also been identified as a potential biomarker for several diseases. The GNG12-AS1 gene has been shown to be involved in the regulation of cellular immigration, which is critical for the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.

Studies have shown that the expression of GNG12-AS1 is significantly altered in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. Therefore, the GNG12-AS1 gene can be used as a biomarker for these diseases.

Conclusion

In conclusion, the GNG12-AS1 gene has the potential to be a drug target and biomarker for several diseases. Its involvement in the regulation of cell cycle progression, apoptosis, and inflammation makes it an attractive target for small molecules. In addition, GNG12-AS1 has been shown to be involved in the regulation of cellular immigration, which is critical for the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders. Further research is needed to confirm its potential as a drug target and biomarker.

Protein Name: GNG12, DIRAS3 And WLS Antisense RNA 1

The "GNG12-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about GNG12-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets